By a News Reporter-Staff News Editor at Drug Week -- A new study on Drugs and Therapies is now available. According to news reporting originating in Beer Sheva, Israel, by NewsRx journalists, research stated, "The blood-brain barrier (BBB) prevents drugs' permeability into the brain and limits management of brain diseases. Specialized drug delivery systems (DDSs) are utterly required to overcome this barrier and to achieve efficient delivery of therapeutic agents to the brain."
The news reporters obtained a quote from the research from the Ben-Gurion University of the Negev, "For this purpose, drug-encapsulating nanoparticles or vesicles, drug conjugates and other types of DDSs are being developed by many research groups worldwide. However, efficiency of the brain drug/DDS delivery and targeting is usually presented in indirect and vague form and it is hard to quantitatively estimate it based on the reported data. We searched for the scientific papers that were published in 1970-2012 that reported delivery of drugs or model compounds to the brain following systemic administration of DDSs via parenteral routes and contained quantitative data on brain drug/DDS delivery and targeting efficiency. We identified 123 publications that matched the search criteria and analyzed their experimental settings, formulation types, analytical methods, and the claimed efficiencies of drug/DDS brain targeting (brain/plasma or brain/tissue concentration ratios) and brain accumulation (% of the administered dose that accumulated in the brain)."
According to the news reporters, the research concluded: "Based on the outcomes of this analysis, we describe the major research trends, discuss the efficiencies of the different drug/DDS brain targeting approaches, and provide recommendations for quantitative assessment of brain-targeting DDSs in the appropriately designed studies."
For more information on this research see: Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems. Journal of Controlled Release, 2013;171(1):17-23. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news correspondents report that additional information may be obtained by contacting L. Kozlovskaya, Ben Gurion University of the Negev, Fac Hlth Sci, Dept. of Clin Biochem & Pharmacol, IL-84105 Beer Sheva, Israel (see also Drugs and Therapies).
Keywords for this news article include: Asia, Israel, Beer Sheva, Drugs and Therapies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC